<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0301-696X</journal-id>
<journal-title><![CDATA[Revista de sanidad militar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. sanid. mil.]]></abbrev-journal-title>
<issn>0301-696X</issn>
<publisher>
<publisher-name><![CDATA[Secretaría de la Defensa Nacional, Dirección General de Sanidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0301-696X2024000100004</article-id>
<article-id pub-id-type="doi">10.56443/q49fzv13</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Observación de los efectos de la colchicina en el síndrome de insuficiencia respiratoria aguda por COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Observation of the effects of colchicine in acute respiratory distress syndrome due to COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-López]]></surname>
<given-names><![CDATA[José Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rugerio Trujillo]]></surname>
<given-names><![CDATA[Deniria A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales Pogoda]]></surname>
<given-names><![CDATA[Irving I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sandoval de la Cruz]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretaria de la Defensa Nacional Hospital Central Militar ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>78</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0301-696X2024000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0301-696X2024000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0301-696X2024000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El síndrome de dificultad respiratoria aguda por COVID-19 es un trastorno infeccioso viral de afección sistémica con predominio de síntomas respiratorios que en nuestro país se manifestó en un 16% la forma grave de la enfermedad, misma que requirió tratamiento en unidades de cuidados intensivos. Sin embargo, ante la sobre saturación de los servicios de salud en todos los niveles, se buscan opciones terapéuticas para frenar la progresión de la enfermedad y con ello evitar el requerimiento de estas unidades.  Objetivo: Observar el efecto de la colchicina como terapia adyuvante al glucocorticoide, sobre los niveles de oxemia en pacientes con síndrome de dificultad respiratoria aguda por COVID-19  Material y métodos: Se revisaron expedientes clínicos del periodo de diciembre 2020 a marzo 2021 de donde se obtuvieron variables clínico-epidemiológicas de 408 pacientes para estadística descriptiva y analítica.  Resultados: Se observó una mayor hospitalización de pacientes hombres en 65.9%, las comorbilidades más prevalentes fueron obesidad e hipertensión arterial los cuales aumentaban la probabilidad de enfermedad por COVID-19 con un OR de 1.7 y 2 veces respectivamente. El uso de colchicina como terapia adyuvante al glucocorticoide disminuyó la mortalidad en formas graves de la enfermedad (OR 0.17), aumentó la probabilidad de egreso por mejoría (OR 5.22) y disminuyó el requerimiento de traslados (OR 6.65). Por otra parte, se encontró que la ventilación en prono despierto es un factor protector en todos los grupos (OR 0.36).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Acute respiratory distress syndrome by COVID-19 is a viral infectious disorder of systemic affection with a predominance of respiratory symptoms that in our country manifested itself in 16% of the severe form of the disease, which required treatment in care units. intensive. However, given the over-saturation of health services at all levels, therapeutic options are sought to slow the progression of the disease and thus avoid the need for these units.  Objective: To observe the effect of colchicine as adjuvant therapy to glucocorticoid, on oxemia levels in patients with acute respiratory distress syndrome due to COVID-19.  Material and methods: Clinical records from the period from December 2020 to March 2021 were reviewed, from which clinical-epidemiological variables of 408 patients were obtained for descriptive and analytical statistics.  Results: A greater hospitalization of male patients was observed in 65.9%, the most prevalent comorbidities were obesity and arterial hypertension, which increased the probability of COVID-19 disease with an OR of 1.7 and 2 times, respectively. The use of colchicine as adjuvant therapy to the glucocorticoid decreased mortality in severe forms of the disease (OR 0.17), increased the probability of discharge due to improvement (OR 5.22) and decreased the need for transfers (OR 6.65). On the other hand, it was found that awake prone ventilation is a protective factor in all groups (OR 0.36).]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[colchicine]]></kwd>
<kwd lng="en"><![CDATA[ARDS]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[colchicina]]></kwd>
<kwd lng="es"><![CDATA[SDRA]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Novel Coronavirus from Patients with Pneumonia in China, 2019]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2020</year>
<volume>382</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>727-33</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[VCC]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[S-C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JHK]]></given-names>
</name>
<name>
<surname><![CDATA[Yip]]></surname>
<given-names><![CDATA[CCY]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[VWM]]></given-names>
</name>
<name>
<surname><![CDATA[Tsang]]></surname>
<given-names><![CDATA[OTY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong]]></article-title>
<source><![CDATA[Infect Control Hosp Epidemiol]]></source>
<year>2020</year>
<volume>41</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>493-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe acute respiratory syndrome (SARS) and coronavirus disease-2019 (COVID-19): From causes to preventions in Hong Kong]]></article-title>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2020</year>
<volume>94</volume>
<page-range>156-63</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Instituto Nacional Electoral</collab>
<source><![CDATA[ACUERDO del Consejo General del Instituto Nacional Electoral por el que se determina la reanudación de plazos para atender las tareas sustantivas y procedimentales atinentes a la materia de fiscalización, bajo la modalidad a distancia o semipresencial, con motivo de la pandemia COVID-19]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>The RECOVERY Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Dexamethasone in Hospitalized Patients with Covid-19]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>693-704</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tardif]]></surname>
<given-names><![CDATA[J-C]]></given-names>
</name>
<name>
<surname><![CDATA[Bouabdallaoui]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[L&#8217;Allier]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Gaudet]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pillinger]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<source><![CDATA[Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deftereos]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Giannopoulos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vrachatis]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Siasos]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Giotaki]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Gargalianos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial]]></article-title>
<source><![CDATA[JAMA Netw Open]]></source>
<year>2020</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Baño]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pachón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carratalà]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jarrín]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yllescas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)]]></article-title>
<source><![CDATA[Clinical Microbiology and Infection]]></source>
<year>2021</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>244-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>National Institutes of Health</collab>
<source><![CDATA[Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update review of emerging small-molecule therapeutic options for COVID-19]]></article-title>
<source><![CDATA[Biomed Pharmacother]]></source>
<year>2021</year>
<volume>137</volume>
<page-range>111313</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gracheva]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Shchegravina]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Schmalz]]></surname>
<given-names><![CDATA[H-G]]></given-names>
</name>
<name>
<surname><![CDATA[Beletskaya]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[Fedorov]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colchicine Alkaloids and Synthetic Analogues: Current Progress and Perspectives]]></article-title>
<source><![CDATA[J Med Chem]]></source>
<year>2020</year>
<volume>63</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>10618-52</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera-García]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Nuche-Salazar]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Peregrina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arizpe-Bravo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neumonía grave por COVID-19 y administración de medicamentos biológicos]]></article-title>
<source><![CDATA[Med Int Mex]]></source>
<year>2020</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>888-94</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupuis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sirois]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Rhéaume]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[QT]]></given-names>
</name>
<name>
<surname><![CDATA[Clavet-Lanthier]]></surname>
<given-names><![CDATA[M-É]]></given-names>
</name>
<name>
<surname><![CDATA[Brand]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colchicine reduces lung injury in experimental acute respiratory distress syndrome]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Veldhuizen]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS ONE]]></source>
<year>2020</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
